Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Alpine Immune Sciences, Inc. - Common Stock
(NQ:
ALPN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alpine Immune Sciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
General Mills, Lennar And 3 Stocks To Watch Heading Into Wednesday
↗
September 21, 2022
With US stock futures trading slightly lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Alpine Immune Sciences Announces Pricing of $100 Million Public Offering
September 20, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Proposed Public Offering
September 20, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
At R&D Day, Alpine Immune Highlights Updates On Autoimmune, Immuno-Oncology Programs
↗
September 13, 2022
Via
Benzinga
Alpine Immune's Davoceticept Monotherapy Reduces Tumors In Early Stage Study
↗
April 13, 2022
Alpine Immune Sciences Inc (NASDAQ: ALPN)
Via
Benzinga
Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day
September 12, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Participation in September Investor Conferences
September 06, 2022
From
Alpine Immune Sciences Inc.
Via
Business Wire
Alpine Immune Sciences's Return On Capital Employed Overview
↗
September 06, 2022
Benzinga Pro data, Alpine Immune Sciences (NASDAQ:ALPN) reported Q2 sales of $5.29 million. Earnings fell to a loss of $18.10 million, resulting in a 140.44% decrease from last quarter.
Via
Benzinga
Alpine Immune Sciences Announces R&D Day to Provide Clinical Updates on Wholly-Owned Programs ALPN-303 and Davoceticept
August 30, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Inducement Grant to Andrew S. Sandler, M.D. Under Nasdaq Listing Rule 5635(c)
August 18, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences: Q2 Earnings Insights
↗
August 11, 2022
Alpine Immune Sciences (NASDAQ:ALPN) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 11, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
↗
August 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Evotec, Alpine Expand Pact For Commercial Process Development Of Autoimmune Disease Candidate
↗
August 10, 2022
Via
Benzinga
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
August 10, 2022
From
Alpine Immune Sciences Inc.
Via
Business Wire
Alpine Immune Sciences Announces Participation in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 04, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of Directors
July 19, 2022
From
Alpine Immune Sciences Inc.
Via
Business Wire
Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer
June 07, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022
June 01, 2022
From
Alpine Immune Sciences Inc.
Via
Business Wire
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
↗
May 30, 2022
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for...
Via
Benzinga
Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings
May 26, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
FDA Lifts Partial Hold On Alpine Immune's Davoceticept Combo Trial In Advanced Cancer
↗
May 24, 2022
Via
Benzinga
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
May 24, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 12, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Participation in May Investor Conferences
May 03, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
AACR 2022: Davoceticept (ALPN-202) Monotherapy Reduces Tumors, Supports Multiple Expansion Cohorts
April 12, 2022
From
Alpine Immune Sciences Inc.
Via
Business Wire
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
↗
April 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
↗
April 10, 2022
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
Via
Benzinga
Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event
April 05, 2022
From
Alpine Immune Sciences Inc.
Via
Business Wire
Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications
April 04, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
